Fiche centre
University of Texas Southwestern Medical Center
Dallas — United States
Essais liés28clinical trials
VilleDallaslocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06211764
Essais cliniques associés
28| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Atezolizumab | Cancer | Phase 2 | NCT06096779 | Kirros — A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | ACTIVE_NOT_RECRUITING |
| Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor | Insuffisance cardiaque | Phase 3 | NCT07018297 | Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure | NOT_YET_RECRUITING |
| Pumitamig | Cancer | Phase 3 | NCT07173751 | ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | RECRUITING |
| VS-041 | Insuffisance cardiaque | Phase 1 | NCT07219511 | A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | ACTIVE_NOT_RECRUITING |
| AFSW Guided DOAC | Accident vasculaire cérébral | Phase 3 | NCT05836987 | REACT-AF — The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | RECRUITING |
| Vicadrostat | Insuffisance cardiaque | Phase 3 | NCT06424288 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | RECRUITING |
| Colchicine 0.5 MG Oral Tablet | Maladie coronarienne | Phase 3 | NCT04774159 | LEADER-PAD — Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk | RECRUITING |
| Transcatheter Aortic Valve Replacement | Maladie rénale chronique | À vérifier | NCT02791880 | Acute Kidney Injury Genomics and Biomarkers in TAVR Study | COMPLETED |
| COBENFY KarXT (50/20 mg) | Épilepsie | Phase 1 | NCT07228338 | Cholinergic Enhancement of Theta | NOT_YET_RECRUITING |
| TAR-200 | Cancer | Phase 3 | NCT06211764 | SunRISe-5 — A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) | ACTIVE_NOT_RECRUITING |
| Stereotactic Radiosurgery | Cancer | Phase 1/2 | NCT03508752 | Neurocognitive Decline in Patients With Brain Metastases | ACTIVE_NOT_RECRUITING |
| Irreversible Electroporation | Cancer | Non applicable | NCT04972097 | PRESERVE — Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue | COMPLETED |
| Zanidatamab | Cancer | Phase 3 | NCT06282575 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | RECRUITING |
| Ocrelizumab | SEP | Phase 4 | NCT04377555 | Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab | COMPLETED |
| Neuropeptide Y | Hypertension | Phase 1 | NCT04838678 | Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN) | RECRUITING |
| Vicadrostat | Hypertension | Phase 3 | NCT07064473 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | RECRUITING |
| Cobenfy KarXT pill (50/20 mg) | Épilepsie | Phase 1 | NCT07721272 | Human Cognition During Surgery: Stimulation-based and Cholinergic Modulation | NOT_YET_RECRUITING |
| Neuraceq | Alzheimer | À vérifier | NCT05617014 | ADNI4 — Alzheimer's Disease Neuroimaging Initiative 4 | ENROLLING_BY_INVITATION |
| TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | SEP | Non applicable | NCT03500328 | TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | ACTIVE_NOT_RECRUITING |
| Telitacicept | Myasthénie | Phase 3 | NCT06456580 | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | ACTIVE_NOT_RECRUITING |
| Vamorolone | Myopathies | À vérifier | NCT06564974 | DMD-001 SUMMIT — Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT | RECRUITING |
| CT1812 | Alzheimer | Phase 2 | NCT05531656 | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 4 | NCT05285891 | AMS05 — Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04548999 | GAVOTTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) | ACTIVE_NOT_RECRUITING |
| Interferon beta-1a | SEP | Phase 3 | NCT01412333 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis | COMPLETED |
| Prednisone | Myasthénie | Phase 3 | NCT00995722 | Efficacy of Prednisone In the Treatment of Ocular Myasthenia | TERMINATED |
| Sacituzumab govitecan-hziy | Cancer | Phase 3 | NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | ACTIVE_NOT_RECRUITING |
| RNS® System | Épilepsie | Phase 4 | NCT00572195 | RNS® System LTT Study | COMPLETED |